Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...

The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology. “We understand that ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.

To access the live and archived webcast, visit the News & Events page of the company's website at . The archived webcast will be available for 30 days following the presentation.

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

Your indoor versus outdoor environment could have an even bigger impact on your eczema symptoms than you realize.

If you’ve been battling with dry, itchy skin, you might be dealing with atopic dermatitis ... For those already dealing with ...